News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Supernus Pharmaceuticals (SUPN) To Receive $30 Million In Non-Dilutive Royalty Deal


7/8/2014 7:22:29 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ROCKVILLE, Md., July 8, 2014 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq:SUPN), today announced the execution of a royalty acquisition agreement ("Agreement") with HealthCare Royalty Partners ("HC Royalty"). Per the Agreement, HC Royalty will make a $30 million cash payment to Supernus in consideration for acquiring from Supernus certain royalty and milestone rights related to the commercialization of Orenitramâ„¢ (treprostinil) Extended-Release Tablets by Supernus' partner United Therapeutics Corporation. Supernus will retain full ownership of the Royalty Rights after a certain threshold has been reached per the terms of the Agreement. - See more at: http://www.globenewswire.com/news-release/2014/07/08/649276/10088026/en/Supernus-to-Receive-30-Million-in-Non-Dilutive-Royalty-Deal.html#sthash.vyAUiSR4.dpuf

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES